1 / 35

Bacterial infections in cirrhosis

Infections and cirrhosis. More frequent complication in patients with cirrhosis (30 to 47% in hospitalized patients) (1) Mortality related factor: 30% vs 5 - 12% (2) The most frequent types of infection: SBP (7 - 31%), urinary (12 - 29%) pulmonary infections (6 - 21%) and bacteremia (10 - 12%)Th

domani
Télécharger la présentation

Bacterial infections in cirrhosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Bacterial infections in cirrhosis Dr Jean-Didier Grangé Hôpital Tenon, Paris, France AP-HP - Université Paris VI

    2. Infections and cirrhosis More frequent complication in patients with cirrhosis (30 to 47% in hospitalized patients) (1) Mortality related factor: 30% vs 5 - 12% (2) The most frequent types of infection: SBP (7 - 31%), urinary (12 - 29%) pulmonary infections (6 - 21%) and bacteremia (10 - 12%) The most severe (mortality): pulmonary (30 à 41%) and SBP (20 à 30 %)

    4. Type of bacteria isolated in SBP Changing epidemiology ?

    7. Prognosis of SBP

    8. Curative treatment of SBP

    9. Cefotaxime - plus - albumin Results Cefotaxime : 2g/6 h IV Albumin (n = 63) 1.5 g/kg within 6 hours of enrollment 1 g/kg on day 3

    10. Cefotaxime - plus - albumin Mortality

    11. Decision criteria

    12. Summary –Treatment of SBP SBP : PMN > 250/ mm3 cefotaxime or amoxicillin/clavulanic acid Prevention of renal insufficiency ? Avoid aminoglycosides, NSAIDs, large volume paracentesis ? Baseline BUN elevation ? albumin Assess response to treatment (48 hours) Uncomplicated SBP : oral therapy with quinolones or amoxicillin-clavulanic acid One year survival : 30 to 40 % – Secondary prophylaxis – Evaluation for liver transplantation

    13. Cirrhosis and pulmonary infections Frequent: 6 to 21% in prospective studies No RCT in patients with cirrhosis Mortality : 30 to 40 % Fine Score

    14.

    15. Community-Acquired Pneumonia Treatment in patients with cirrhosis

    16. Treatment of infections (n=96) Cefotaxime vs amoxicilline/clavulanate

    17. Moxifloxacin vs amoxicilline/clavulanate Type of infections (4 countries, 28 centers)

    18. Treatment of infections (n=143)

    19. SBP resolution (n = 35)

    20. Pneumonia resolution (n = 21)

    21. Prophylaxis Patients with ascites who are recovering from a prior episode of SBP Those with an ascitic albumin concentration of les than 10g/L Those with gastrointestinal bleeding

    22. Prevent recurrence of SBP (n = 80)

    23. Antibiotic prophylaxis in hospitalized patients ascites protein < 15 g/L (n = 63)

    24. Patients without prior SBP ascites protein < 15g/L (n=107)

    25. Long-term prophylaxis in patients with ascites - Meta-analysis 4 RCT, 1 meta-analysis

    26. Selection of highly resistant Gram-negative pathogens and risk of emergence of enterococcus and methicillin-resistant Staphylococcus aureus. Campillo B et al. Epidemiol Infect 2001;127:443-50 Factors of development of quinolone-resistant negative Gram bacilli : Length of antibiotic prophylaxis Prevalence rate of quinolone resistance in care unit, hospital or country Immunosuppression (steroid therapy, HIV, cancer) Cereto F et al. Eur J Gastroenterol Hepatol 2002;14:81-3 Risks of antibiotic prophylaxis

    28. Antibiotic prophylaxis and early rebleeding

    29. Variceal bleeding in patients with cirrhosis In-hospital mortality

    30. Predictors of survival Multivariable analysis Lower Child-Pugh Score Absence of hypovolemic shock Endoscopic therapy (? pharmacological therapy) Antibiotic prophylaxis Younger age

    31. Short-term prophylaxis Effective in the prevention of infections, significant improvement in survival Short-term prophylaxis should be considered standard of care in cirrhotic patients admitted with GI hemorrhage Norfloxacin : 400 mg BID or ofloxacin for 7 days Hospitalized patients with ascites protein < 10 g/L: - Norfloxacin 400 mg/d during hospitalization stay

    32. Long-term prophylaxis Effective in the prevention of infections, risk of bacterial resistance Patients recovering from an episode of SBP : norfloxacin 400 mg QD until disappearance of ascites, transplant or death Patients without prior SBP and ascites protein < 10g/L. The indication depends of individual infection risk, therapeutic plan and local bacterial ecology Patients without prior SBP and ascites protein > 10g/L. ? antibiotic prophylaxis is no recommended

    34. Norfloxacine et prokinétiques Prospectif Simple aveugle Contrôlée, randomisée

    35. Norfloxacine et prokinétiques

More Related